(Q35166813)

6 August 2017

1 reference

title

Ovarian cancer: strategies for overcoming resistance to chemotherapy (English)

1 reference

6 August 2017

1 reference

1 reference

Roshan Agarwal

1

1 reference

PubMed ID

12835670

6 August 2017

Stan B Kaye

series ordinal

2

1 reference

PubMed ID

12835670

6 August 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

6 August 2017

Nature Reviews Cancer

1 reference

6 August 2017

3

1 reference

6 August 2017

502-516

1 reference

6 August 2017

7

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc1123

6 August 2017

0 references

cites work

Surgical management of ovarian cancer

1 reference

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group

31 March 2020

1 reference

Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma

31 March 2020

1 reference

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

31 March 2020

1 reference

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

31 March 2020

1 reference

First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer--a new standard of care?

31 March 2020

1 reference

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

31 March 2020

1 reference

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

31 March 2020

1 reference

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

31 March 2020

1 reference

First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence

31 March 2020

1 reference

31 March 2020

Cancer statistics, 2001

1 reference

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

31 March 2020

1 reference

Recent advances in the treatment of epithelial ovarian cancer

31 March 2020

1 reference

Recognition of cisplatin adducts by cellular proteins

31 March 2020

1 reference

Cellular and molecular determinants of cisplatin resistance

31 March 2020

1 reference

Identification of genes that mediate sensitivity to cisplatin.

31 March 2020

1 reference

Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death

31 March 2020

1 reference

The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review

31 March 2020

1 reference

The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex

31 March 2020

1 reference

Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis

31 March 2020

1 reference

Pharmacogenetics and cancer chemotherapy

31 March 2020

1 reference

Hypoxia and drug resistance

31 March 2020

1 reference

Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo.

31 March 2020

1 reference

Acquired multicellular-mediated resistance to alkylating agents in cancer

31 March 2020

1 reference

Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents

31 March 2020

1 reference

The clonal evolution of tumor cell populations

31 March 2020

1 reference

A family of drug transporters: the multidrug resistance-associated proteins.

31 March 2020

1 reference

Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma.

31 March 2020

1 reference

Expression of P-glycoprotein in epithelial ovarian cancer: evaluation as a marker of multidrug resistance

31 March 2020

1 reference

High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis

31 March 2020

1 reference

Glutathione S-transferase activity in epithelial ovarian cancer: Association with response to chemotherapy and disease outcome

31 March 2020

1 reference

Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes

31 March 2020

1 reference

Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization

31 March 2020

1 reference

Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours

31 March 2020

1 reference

ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients

31 March 2020

1 reference

Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy

31 March 2020

1 reference

hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents

31 March 2020

1 reference

Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors

31 March 2020

1 reference

The biochemistry of apoptosis

31 March 2020

1 reference

Immunohistochemically detected p53 mutations in epithelial tumors and results of treatment with chemotherapy and radiotherapy. A treatment-specific overview of the clinical data.

31 March 2020

1 reference

The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol

31 March 2020

1 reference

Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status

31 March 2020

1 reference

P53 mutation in a series of epithelial ovarian cancers from the U.K., and its prognostic significance

31 March 2020

1 reference

Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer.

31 March 2020

1 reference

Apoptosis: a link between cancer genetics and chemotherapy

31 March 2020

1 reference

Cisplatin resistance is associated with reduced interferon-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells

31 March 2020

1 reference

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

31 March 2020

1 reference

Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas

31 March 2020

1 reference

Proliferation, cell cycle and apoptosis in cancer

31 March 2020

1 reference

Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (ISIS 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype

31 March 2020

1 reference

Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein

31 March 2020

1 reference

Factors determining cellular mechanisms of resistance to antimitotic drugs

31 March 2020

1 reference

Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione

31 March 2020

1 reference

Development of a syngeneic mouse model for events related to ovarian cancer

31 March 2020

1 reference

Induction of ovarian cancer by defined multiple genetic changes in a mouse model system

31 March 2020

1 reference

Modelling the molecular circuitry of cancer

31 March 2020

1 reference

Statistical aspects of prognostic factor studies in oncology

31 March 2020

1 reference

Metallothionein levels in ovarian tumours before and after chemotherapy

31 March 2020

1 reference

Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis

31 March 2020

1 reference

Genome changes and gene expression in human solid tumors

31 March 2020

1 reference

Gene expression profiling predicts clinical outcome of breast cancer

31 March 2020

1 reference

Future directions in the treatment of ovarian cancer

31 March 2020

1 reference

Dose intensity analysis of chemotherapy regimens in ovarian carcinoma

31 March 2020

1 reference

Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group

31 March 2020

1 reference

Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group

31 March 2020

1 reference

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

31 March 2020

1 reference

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

31 March 2020

1 reference

Tumor targeting by conjugation of DHA to paclitaxel

31 March 2020

1 reference

A phase II trial of ZD0473 in platinum-pretreated ovarian cancer.

31 March 2020

1 reference

Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.

31 March 2020

1 reference

Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients

31 March 2020

1 reference

New paradigms in the treatment of breast and colorectal cancer--an introduction

31 March 2020

1 reference

Mechanism of action of rituximab

31 March 2020

1 reference

Design and synthesis of Cyclopenta[g]quinazoline-based antifolates as inhibitors of thymidylate synthase and potential antitumor agents(,).

31 March 2020

1 reference

Relationship between folate-binding protein expression and cisplatin sensitivity in ovarian carcinoma cell lines

31 March 2020

1 reference

Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer

31 March 2020

1 reference

A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy

31 March 2020

1 reference

Cellular glutathione content, in vitro chemoresponse, and the effect of BSO modulation in samples derived from patients with advanced ovarian cancer

31 March 2020

1 reference

Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.

31 March 2020

1 reference

Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines.

31 March 2020

1 reference

Phase I and clinical pharmacological evaluation of aphidicolin glycinate

31 March 2020

1 reference

Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500

31 March 2020

1 reference

A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer

31 March 2020

1 reference

Pharmacological rescue of mutant p53 conformation and function

31 March 2020

1 reference

The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic Bax/mitochondrial/caspase-9 pathway.

31 March 2020

1 reference

Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial

31 March 2020

1 reference

The EGF receptor family as targets for cancer therapy

31 March 2020

1 reference

Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies

31 March 2020

1 reference

Farnesyl transferase inhibitors: a novel targeted tnerapy for cancer

31 March 2020

1 reference

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

31 March 2020

1 reference

Proteasome inhibition: a novel approach to cancer therapy

31 March 2020

1 reference

Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial

31 March 2020

1 reference

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

31 March 2020

1 reference

Sequence-dependent antitumor activity of paclitaxel (taxol) and cisplatin in vivo

31 March 2020

1 reference

Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma

31 March 2020

1 reference

Future directions for the management of ovarian cancer

31 March 2020

1 reference

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

31 March 2020

1 reference

The combined use of radiotherapy and chemotherapy in the treatment of solid tumours

31 March 2020

1 reference

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

31 March 2020

1 reference

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

31 March 2020

1 reference

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

31 March 2020

1 reference

Cellular glutathione (GSH) and glutathione S-transferase (GST) activity in human ovarian tumor biopsies following exposure to alkylating agents

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRC1123

1 reference

6 August 2017

1 reference

PubMed ID

12835670